On Sept. 16, 2018, the investigator meeting for LAE001CN2101 clinical trial of testing LAE001 for prostate cancer was successfully held by Laekna Therapeutics in Shanghai Pullman hotel.

The meeting was hosted by Professor Dingwei Ye (Vice President International Affairs & Professor, Chairman of Department of Urology, Director of the Multidisciplinary Team Approach for Genitourologic Malignancies, Fudan University Shanghai Cancer Center; Vice Chairman of Genitourinary Cancer Committee of China Anti-Cancer Association; Decisive Reviewer of National Natural Science Foundation of China; Executive of Asian Pacific Prostate Society). Meeting participants included Professor Qing Zhou from Jiangsu Cancer Hospital, Professor Zhongquan Sun from Huadong Hospital, Attending Physician Qi Long from Zhongshan Hospital and the clinical team from Laekna Therapeutics.

Dr. Chris Lu, CEO, Laekna Therapeutics expressed his warmly thanks to all the key opinion leaders (KOLs) for their support for LAE001CN2101 project. LAE001 is a novel, non-steroid, potent reversible dual inhibitor of Cytochrome P450 (CYP) 17 and CYP11B2. It treats prostate cancer mainly through inhibition of the synthesis of testosterone and aldosterone. LAE001CN2101 project is a clinical phase I/II trial targeting the patients with Metastatic Castration-Resistant and Castration-Sensitive Prostate Cancer in China. 

Dr. Yu Wang, who is leading LAE001CN2101 study, presented the results of phase I/II clinical study of LAE001 in US, introduced the clinical study protocol of LAE001CN2101, and proposed the clinical strategy to develop LAE001 in China and outside of China. After Dr. Wang’s presentation, the KOLs provided their thoughts and comments, which led to a heated discussion among all participants on the study details such as study protocol, inclusion criteria, etc. 

Professor Dingwei Ye concluded the meeting and wished all the success to LAE001CN2101 study.